PNC Financial Services Group’s 4D Molecular Therapeutics FDMT Stock Holding History

PNC Financial Services Group’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.7K	Buy	1,482 +20	+1%	+$195	﹤0.01%	3788
2026 Q1	$13.6K	Sell	1,462 -5,713	-80%	-$49.7K	﹤0.01%	3847
2025 Q4	$53.8K	Sell	7,175 -131	-2%	-$1.33K	﹤0.01%	3171
2025 Q3	$63.5K	Sell	7,306 -1,854	-20%	-$11.1K	﹤0.01%	3065
2025 Q2	$34K	Buy	9,160 +1,257	+16%	+$4.42K	﹤0.01%	3326
2025 Q1	$25.5K	Sell	7,903 -1,221	-13%	-$5.75K	﹤0.01%	3430
2024 Q4	$50.8K	Buy	9,124 +3,630	+66%	+$28.5K	﹤0.01%	3097
2024 Q3	$59.4K	Buy	5,494 +1,134	+26%	+$18.8K	﹤0.01%	2989
2024 Q2	$91.5K	Buy	4,360 +4,332	+15,471%	+$109K	﹤0.01%	2687
2024 Q1	$892	Sell	28 -4	-13%	-$102	﹤0.01%	4386
2023 Q4	$648	Buy	+32	New	+$421	﹤0.01%	4372

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

PNC Financial Services Group's FDMT Position: Q2 2026 in Review

PNC Financial Services Group increased its 4D Molecular Therapeutics (FDMT) stake by 1.4% in Q2 2026, buying an estimated $195 and bringing the position to 1,482 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3788.

PNC Financial Services Group first reported a position in FDMT in Q4 2023 and has held it in 11 quarters since. The position peaked at $91.5K in Q2 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

PNC Financial Services Group held 1,482 shares of 4D Molecular Therapeutics worth $19.7K as of Q2 2026.
PNC Financial Services Group bought 20 4D Molecular Therapeutics shares in Q2 2026, an estimated $195.
4D Molecular Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3788 holding.
PNC Financial Services Group first reported a position in 4D Molecular Therapeutics in Q4 2023 and has held it in 11 quarters since.
PNC Financial Services Group's 4D Molecular Therapeutics position peaked at $91.5K in Q2 2024.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.